MG
Matthew Gline (CEO) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in Roivant Sciences Ltd. (ROIV). The largest single filing was $37.7M of ROIV (1,740,000 sh across 3 lots, as filed), executed Dec 15 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
2
0 buys · 2 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$46.2M
shares × price, as filed
Last traded
Apr 16
Filed Apr 20
Median ADV $222.0M across their filed names
Open performance→Volume by month
Buys $0
Sells $46.2M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
ROIVRecent filings
ROIVSALE
Roivant Sciences Ltd.
View filing →
$8.4M289,774 sh × $29.16
Exec Apr 16
Filed Apr 20 · 5:30 PM ET ROIVSALE Roivant Sciences Ltd. View filing → $37.7M
1,740,000 sh across 3 lots
Exec Dec 15 2025
Filed Dec 17 2025 · 5:30 PM ET